Drug Trial Radar · NCT06939283
A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Apr 21, 2025
Primary completion
Apr 23, 2026
Study completion Apr 23, 2026
Sponsor
- Lead sponsor
- Werewolf Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety and tolerability of the study drug WTX-330 when administered using a fixed dose regimen or a step-up dose regimen in adult patients with selected advanced or metastatic solid tumors or lymphoma. In addition to safety and tolerability, the study aims to: * determine the maximum initial dose of WTX-330 that may be used in the step-up dose regimen * determine whether the step-up dose regimen can increase WTX-330 exposure in patients due to improved tolerability * determine the maximum tolerated dose (MTD) of WTX-330 and/or recommended dose for expansion (RDE) for each regimen * evaluate the antitumor activity of WTX-330 * characterize the pharmacokinetic (PK) profile of WTX-330 * characterize the interferon gamma (IFNγ) profile after treatment with WTX-330 * evaluate changes in immunological biomarkers * determine the impact of WTX-330 on overall survival (OS) Study participants will participate in a dose- and regimen-finding phase (Part 1) followed by a dose expansion phase (Part 2) where they will be assigned to one of three arms (A, B and C).
Conditions
- Advanced or Metastatic Solid Tumors
- Non-Hodgkin Lymphoma
Interventions
WTX-330Drug
Investigational Product
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose Limiting Toxicities (DLTs)Time frame: 4 weeks
- Incidence of treatment emergent adverse eventsTime frame: 24 months
- Incidence of changes in clinical laboratory abnormalitiesTime frame: 24 months
- Overall response rate (ORR) by response evaluation criteria in solid tumors (RECIST) 1.1 and the immune-overall response rate (iORR) by immune RECIST (iRECIST; Part 2, Arms A and B) or response by Lugano classification (Part 2, Arm C)Time frame: 24 months
- Duration of response (DOR) by response evaluation criteria in solid tumors (RECIST) 1.1 and immune RECIST (iRECIST; Part 2, Arms A and B) or based on Lugano classification (Part 2, Arm C)Time frame: 24 months
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
HonorHealth Research Institute
Scottsdale, Arizona
Emory Winship Cancer Institute
Atlanta, Georgia
Northwestern University
Chicago, Illinois
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana
NEXT Oncology
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.